- Autolus Therapeutics plc AUTL has granted Moderna Inc MRNA an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus' proprietary binders for up to four immuno-oncology targets.
- Autolus would be eligible to receive an upfront payment for each target licensed by Moderna and milestone payments.
- In addition, Autolus would be entitled to receive royalties on net sales.
- Price Action: AUTL shares are up 16.9% at $6.22, while MRNA stock is +2.1% at $360.95 during the premarket session on the last check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.